Health Care [ 9/12 ] | Biotechnology [ 61/74 ]
NASDAQ | Common Stock
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs.
It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA.
It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases.
The company was incorporated in 2009 and is based in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 25, 25 | -0.29 Increased by +60.27% | -0.40 Increased by +27.84% |
| Nov 5, 24 | -0.46 Increased by +60.48% | -0.30 Decreased by -54.13% |
| Aug 1, 24 | -0.28 Increased by +72.55% | -0.32 Increased by +12.50% |
| May 7, 24 | -0.42 Increased by +73.08% | -0.47 Increased by +10.64% |
| Feb 27, 24 | -0.73 Increased by +51.33% | -0.69 Decreased by -5.80% |
| Nov 1, 23 | -1.17 Increased by +33.14% | -0.86 Decreased by -36.05% |
| Jul 31, 23 | -1.02 Increased by +30.14% | -1.32 Increased by +22.73% |
| May 4, 23 | -1.56 Decreased by -9.86% | -1.46 Decreased by -6.85% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 212.53 M Increased by +45.19% | -36.35 M Increased by +58.96% | Decreased by -17.11% Increased by +71.73% |
| Sep 30, 24 | 196.83 M Increased by +98.45% | -57.45 M Increased by +59.04% | Decreased by -29.19% Increased by +79.36% |
| Jun 30, 24 | 199.69 M Increased by +110.26% | -37.66 M Increased by +69.14% | Decreased by -18.86% Increased by +85.32% |
| Mar 31, 24 | 172.32 M Increased by +284.26% | -66.42 M Increased by +62.64% | Decreased by -38.55% Increased by +90.28% |
| Dec 31, 23 | 146.38 M Increased by +545.89% | -88.58 M Increased by +46.64% | Decreased by -60.51% Increased by +91.74% |
| Sep 30, 23 | 99.18 M Increased by +349.68% | -140.24 M Increased by +26.68% | Decreased by -141.39% Increased by +83.70% |
| Jun 30, 23 | 94.97 M Increased by +481.85% | -122.04 M Increased by +21.76% | Decreased by -128.50% Increased by +86.55% |
| Mar 31, 23 | 44.85 M Increased by +211.84% | -177.78 M Decreased by -27.96% | Decreased by -396.42% Increased by +58.97% |